Compare Boston Scientific Corporation (BSX) vs ServiceNow Inc (NOW) Price & Performance

Boston Scientific (BSX) trades at $49.31, up slightly by 0.02% on the day, with a bullish technical signal from moving averages despite overbought RSI readings near 77–83. The company reported strong Q2 2026 results, beating EPS estimates with $0.86 actual versus $0.835 expected, and revenue growth of 7.5%. Fundamentals show robust profitability with a net income margin of 17.5% and ROE of 15.52%, though 2026 guidance was trimmed due to WATCHMAN and electrophysiology segment pressures.

BSX presents a compelling investment case with 86% analyst buy ratings and a $67.21 consensus price target implying 36% upside. Key risks include competitive pressures in medical devices and execution on cost savings. The stock's valuation at a P/E of 19.96 appears reasonable given earnings growth, but investors must weigh near-term headwinds against long-term innovation catalysts.

ServiceNow (NOW) trades at $127.54, up 2.13% with strong technical momentum. The stock shows robust fundamentals with 2025 revenue reaching $13.28B and net income of $1.75B, though valuation ratios remain elevated (P/E 78.05). Recent earnings performance has been mixed with Q2 2026 beating expectations but Q1 missing. Technical indicators show bullish moving averages but overbought RSI signals. The company maintains strong analyst support with 87% buy ratings and a $138.26 consensus target.

ServiceNow presents a compelling growth story with AI-driven expansion opportunities, though premium valuation requires careful risk assessment. Key risks include competitive pressures in enterprise software and execution challenges in maintaining high growth rates. The stock's current technical overbought condition suggests potential near-term consolidation before further upside potential toward analyst targets.